Author details

Full Name

Matthew D Galsky

Affiliation

ORCID

Career Start Year

2000

Papers

371

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37537088	A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.	Clin Genitourin Cancer	2024
37608154	Turning up the heat: CTLA4 blockade in urothelial cancer.	Nat Rev Urol	2024
36919916	Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): aÂ plain language summary.		2023
36300304	Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.	Japanese Journal of Clinical Oncology	2023
36326731	Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.	JAMA Oncol	2023
35788726	Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.	Journal of Cancer Research and Clinical Oncology	2023
36437155	IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer.	Urol Oncol	2023
36394867	Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.	JAMA Oncology	2023
36394849	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.	JAMA Oncol	2023
37607770	Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.	J Immunother Cancer	2023
37751561	Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.	J Clin Oncol	2023
37870949	Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.	N Engl J Med	2023
37954037	Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.		2023
37217695	Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer.	Nat Rev Urol	2023
36519763	Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.		2023
37410974	Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.		2023
37208230	Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.		2023
37069029	Adaptive Immunity in Genitourinary Cancers.	Eur Urol Oncol	2023
36868932	Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.		2023
37366420	Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy-Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling.		2023
35347124	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.	Nat Commun	2022
35715285	Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.	Ann Oncol	2022
36099881	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.	Cancer Cell	2022
35960456	Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.	Discover Oncology	2022
35581143	Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations.	European urology oncology	2022
36031173	Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.		2022
36289743	Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.	Biomedicines	2022
35438782	Phase II Clinical and Translational Study of Everolimus Â± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.	Oncologist	2022
35383003	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival.	Clin Genitourin Cancer	2022
35553053	Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.	Cancer	2022
36333289	Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.	Nat Commun	2022
36129800	Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and TgfÎ²-Dependent Mechanisms.	Mol Cancer Ther	2022
35927156	Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls.	Urologic Oncology: Seminars and Original Investigations	2022
35918812	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.	J Natl Cancer Inst	2022
35471602	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.	Cancer Immunol Immunother	2022
36404878	Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology.	Clinical Epidemiology	2022
35851878	Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.	Nat Med	2022
34288217	Editorial for "Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-Treatment Patients with Bladder Cancer: A Prospective Single-Center Study".	Journal of Magnetic Resonance Imaging	2022
34226662	The obesity paradox in metastatic castration-resistant prostate cancer.	Prostate Cancer and Prostatic Diseases	2022
32665122	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.	Urologic Oncology: Seminars and Original Investigations	2022
35062177	Usability Inspection of a Mobile Cancer Telerehabilitation System.		2022
35288066	Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.	European urology oncology	2022
34508246	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.	Nat Rev Urol	2022
34782263	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.	Clin Genitourin Cancer	2022
35168844	Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.	Eur Urol	2022
35347282	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.	Nat Med	2022
34646777	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.	Frontiers in Oncology	2021
34077643	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.	New England Journal of Medicine	2021
33906099	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.	Eur J Cancer	2021
33746047	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.	Ann Oncol	2021